Recently, glucagon-like peptide 1 (GLP-1) agonists, including semaglutide and liraglutide, have attracted attention for their potential effects on both glycemic control and cardiovascular health and have shown favorable effects in the reduction of MACE in type 2 diabetic patients [8]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.